James Dignam to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications James Dignam has written about Clinical Trials, Phase III as Topic.
Connection Strength
0.960
-
Comparison of futility monitoring guidelines using completed phase III oncology trials. Clin Trials. 2017 Feb; 14(1):48-58.
Score: 0.505
-
Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol. 2008 Aug 20; 26(24):4027-34.
Score: 0.288
-
Integrated phase II/III clinical trials in oncology: a case study. Clin Trials. 2012 Dec; 9(6):741-7.
Score: 0.097
-
A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02. Clin Cancer Res. 2014 Dec 15; 20(24):6379-88.
Score: 0.028
-
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst. 2011 Oct 19; 103(20):1498-506.
Score: 0.022
-
Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol. 2010 May 20; 28(15):2544-8.
Score: 0.020